Evidence map›Paper›PMID 1516769›Full record

ReviewDiabetologia1992

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview.

R A DeFronzo

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00194896 (Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes), which is not on this map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00194896 nacompletednot on this mapstarted 2000, after this paper: background citation

Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes

TypeinterventionalSponsorUniversity of WashingtonRan2000 to 2008Enrolled64ConditionsType 2 Diabetes MellitusArmsrosiglitazone, glyburide
3 · Its place in the literature

Who cites it

83 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

R A DeFronzoDivision of Diabetes, University of Texas Health Science Center, San Antonio.

Funding

ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI THOMPSON, IAN M. · 1985 to 2008
$23.1M
SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · YALE UNIVERSITY · PI RALPH A DEFRONZO · 1986 to 2026
$12.7M
Regulation of Hepatic and Peripheral Glucose MetabolismR56DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DEFRONZO, RALPH A · 2005 to 2005
$73k
NCRR NIH HHS M01-RR-01346NIDDK NIH HHS DK 24092
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2HumansInsulinInsulin ResistanceInsulin SecretionIslets of LangerhansLiverMusclesInsulin

Identifiers

PMID1516769

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.